Global Hyperlipidemia Market, By Type (Familial, Acquired), Treatment (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the hyperlipidemia market is anticipated to grow rapidly during the forecast period. Hyperlipidemia is a highly prevalent condition, especially in wealthy countries. It's also on the rise globally. 94 million persons over the age of 20 in the United States have high total cholesterol levels. This equates to around half of all adults in the United States. People with untreated hyperlipidemia are twice as likely as those with normal cholesterol levels to develop coronary artery disease (CAD). This can cause clogged arteries, which can lead to heart attacks, strokes, and other dangerous complications. On the other hand, hyperlipidemia is usually very treatable, and these emergency situations can be avoided.
Data Bridge Market Research analyses that the hyperlipidemia market was valued at USD 18.97 billion in 2021 and is expected to reach USD 23.84 billion by 2029, registering a CAGR of 2.90% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Hyperlipidemia is referred to a medical condition described by the high fat levels in the bloodstream. Stroke, peripheral vascular disease, obesity, atherosclerosis, hypertension, diabetes and cardiovascular disorders can all be caused by abnormally elevated lipids and/or lipoprotein levels. Genetic factors, bad lifestyles, and a poor diet are the most common causes. Statins, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, bile acid sequestrants, fibric acid derivatives or fibrates, and combination and other antihyperlipidemic medicines are some of the most regularly used hyperlipidemia treatments. This condition is also termed as high cholesterol.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Familial, Acquired), Treatment (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Amgen Inc. (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Alnylam Pharmaceuticals, Inc. (U.S.), Dr. Reddy's Laboratories Ltd. (India), Esperion Therapeutics, Inc. (U.S.), Formac Pharmaceuticals N.V. (Belgium)
|
|
Market Opportunities
|
|
Hyperlipidemia Market Dynamics
Drivers
- Increasing prevalence of hyperlipidemia
The rising prevalence of hyperlipidemia across the globe is estimated to enhance the market's growth. Along with this, the rising awareness among population about the risk of cardiovascular diseases due to persistent hypercholesterolemia will propel the growth rate of hyperlipidemia market. According to World Health Organization (WHO), cardiovascular diseases (CVDs) claimed the lives of 17.9 million individuals worldwide in 2019, accounting for 32% of all deaths.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of hyperlipidemia market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing number of geriatric population
The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to cholesterol and cardiovascular diseases, further estimated to enhance the market's growth rate.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hyperlipidemia market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of hyperlipidemia market. Surging use of statin therapy and rising incidences of obesity are the major factors anticipated to flourish the market's growth rate during the forecast period of 2022-2029.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hyperlipidemia market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of hyperlipidemia during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hyperlipidemia market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This hyperlipidemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hyperlipidemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Hyperlipidemia is a chronic, progressive condition that necessitates dietary and lifestyle adjustments and the use of additional lipid-lowering drugs. Patients with premature coronary artery disease (CAD), defined as CAD that develops in males before the age of 55 to 60 and females before the age of 65, had the greatest level of hyperlipidemia. Hyperlipidemia is around 75-85 percent in the above-mentioned circumstances, compared to 40 to 48 percent in a control population of the same age, but without early coronary artery disease.
Hyperlipidemia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Hyperlipidemia Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the hyperlipidemia market.
Recent Development
- In December 2021, Novartis announced the U.S. Food and Drug Administration (FDA) approval of Leqvio (inclisiran). It is the first and only small interfering RNA (siRNA) therapy that lowers low-density lipoprotein cholesterol with two doses annually, after an initial dose and one at three months. Leqvio lowers LDL-C levels in the bloodstream by enhancing the liver's natural ability to suppress the creation of a protein that contributes to excessive cholesterol levels in the bloodstream.
Global Hyperlipidemia Market Scope
The hyperlipidemia market is segmented on the basis of type, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Familial
- Acquired
Treatment
- Statins
- PCSK9 Inhibitors
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibric Acid Derivatives
- Combination
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Hyperlipidemia Market Regional Analysis/Insights
The hyperlipidemia market is analysed and market size insights and trends are provided by country, type, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the hyperlipidemia market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the hyperlipidemia market because of the rising prevalence of hyperlipidemia and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to increasing number of geriatric population in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel themarket's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Hyperlipidemia Market Share Analysis
The hyperlipidemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hyperlipidemia market.
Some of the major players operating in the hyperlipidemia market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Bristol-Myers Squibb Company (U.S.)
- Eli Lilly and Company (U.S.)
- Regeneron Pharmaceuticals Inc. (U.S.)
- Amgen Inc. (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Alnylam Pharmaceuticals, Inc. (U.S.)
- Dr. Reddy's Laboratories Ltd. (India)
- Esperion Therapeutics, Inc. (U.S.)
- Formac Pharmaceuticals N.V. (Belgium)
SKU-